Urovant Sciences (Urovant Sciences) Purchase Of Investment : $0.00 Mil (TTM As of Dec. 2020)

View and export this data going back to 2018. Start your Free Trial

What is Urovant Sciences Purchase Of Investment?

Urovant Sciences's purchase of investment for the three months ended in Dec. 2020 was $0.00 Mil. It means Urovant Sciences spent $0.00 Mil on purchasing investments. Urovant Sciences's purchase of investment for the trailing twelve months (TTM) ended in Dec. 2020 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Sep. 2020 ), Urovant Sciences spent the same money on purchasing investments in Dec. 2020 ($0.00 Mil).

Urovant Sciences Purchase Of Investment Historical Data

The historical data trend for Urovant Sciences's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Urovant Sciences Purchase Of Investment Chart

Urovant Sciences Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Purchase Of Investment

Urovant Sciences Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Purchase Of Investment	Get a 7-Day Free Trial											-	-	-	-	-

Urovant Sciences Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Urovant Sciences Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Urovant Sciences's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Urovant Sciences (Urovant Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Urovant Sciences Ltd (NAS:UROV) » Definitions » Purchase Of Investment

Comparable Companies

Traded in Other Exchanges

N/A

Address

11-12 St. Jamesâ€™s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB

Website

https://www.urovant.com

Urovant Sciences Ltd is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's pipeline products include Overactive Bladder (OAB), OAB in Men with Benign Prostatic Hyperplasia (BPH), and IBS-Associated Pain.

Executives

Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
Sef Kurstjens	director	C/O UROVANT SCIENCES, INC. 5281 CALIFORNIA AVENUE, SUITE 100 IRVINE CA 92617
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
James M. Hindman	director	2525 DUPONT DRIVE, IRVINE CA 92612
Walt Johnston	officer: SVP, Commercial, USI	UROVANT SCIENCES LTD. 5281 CALIFORNIA AVE SUITE 100 IRVINE CA 92617
Haag-molkenteller Cornelia	officer: CMO/Urovant Sciences, Inc.	C/O UROVANT SCIENCES, INC. 5281 CALIFORNIA AVENUE, SUITE 100 IRVINE CA 92617
Bryan E. Smith	officer: GC/Urovant Sciences, Inc.	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Christine Ocampo	officer: PAO;CAO/Urovant Sciences, Inc	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Ajay Bansal	officer: PFO;CFO/Urovant Sciences, Inc.	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Robinson James A. Jr.	director, officer: PEO;CEO/Urovant Sciences, Inc.	852 WINTER STREET, WALTHAM MA 02451
Sumitomo Chemical Co., Ltd.	other: See Footnote (1)	7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Sumitovant Biopharma Ltd.	10 percent owner	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd	other: See Footnote (1)	6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045
Keith Katkin	director, officer: PEO;CEO/Urovant Sciences, Inc.	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Shigeyuki Nishinaka	director	5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617